Wang Tao, Xiao Shifu, Liu Yuanyuan, Lin Zhiguang, Su Ning, Li Xia, Li Guanjun, Zhang Mingyuan, Fang Yiru
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Alzheimer's Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China.
Int J Geriatr Psychiatry. 2014 Jul;29(7):713-9. doi: 10.1002/gps.4053. Epub 2013 Dec 7.
Early diagnosis of Alzheimer's disease (AD) is imperative for the prevention of disease progression and the development of effective treatments.
Clinically, AD diagnosis has been based on adherence to clinical criteria. It has recently been proposed that diagnostic criteria should also incorporate biomarker findings. However, the most studied candidates or group of candidates for AD biomarkers, including pathological processes and proteins, needs further research. The current study aimed to investigate the capabilities of the following plasma proteins in the diagnosis of AD and amnesia mild cognitive impairment (aMCI): peripheral interleukin (IL) 10, IL-6, amyloid-β (Aβ) 40, Aβ42, phosphorylated tau 181, and total tau.
In addition to 122 normal control (NC) group, 97 AD patients and 54 aMCI patients were recruited for this study. An enzyme-linked immunosorbent assay was used to analyze the concentration of the following blood plasma biomarkers: IL-10, IL-6, Aβ40, Aβ42, phosphorylated tau 181, and total tau.
A one-way analysis of variance (one-factor analysis of variance) of Aβ40 and IL-10 levels revealed a statistically significant difference between the three groups (p < 0.001 and p = 0.020). Using Aβ40 ≥ 42.70 pg/ml as the cut-off point, the sensitivity of the ability of Aβ40 to discriminate between AD and NC groups was 80.0%, and specificity was 69.6%.
The plasma Aβ40 biomarker was able to distinguish between AD and NC groups. However, the plasma biomarkers in the present research were not able to distinguish between aMCI and NC groups.
阿尔茨海默病（AD）的早期诊断对于预防疾病进展和开发有效治疗方法至关重要。
临床上，AD诊断一直基于遵循临床标准。最近有人提出诊断标准还应纳入生物标志物检测结果。然而，AD生物标志物研究最多的候选物或候选物组，包括病理过程和蛋白质，仍需进一步研究。本研究旨在探讨以下血浆蛋白在AD和遗忘型轻度认知障碍（aMCI）诊断中的能力：外周白细胞介素（IL）10、IL-6、淀粉样β蛋白（Aβ）40、Aβ42、磷酸化tau 181和总tau蛋白。
除122名正常对照组（NC）外，本研究招募了97名AD患者和54名aMCI患者。采用酶联免疫吸附测定法分析以下血浆生物标志物的浓度：IL-10、IL-6、Aβ40、Aβ42、磷酸化tau 181和总tau蛋白。
Aβ40和IL-10水平的单因素方差分析显示三组之间存在统计学显著差异（p < 0.001和p = 0.020）。以Aβ40≥42.70 pg/ml为临界值，Aβ40区分AD组和NC组的能力的敏感性为80.0%，特异性为69.6%。
血浆Aβ40生物标志物能够区分AD组和NC组。然而，本研究中的血浆生物标志物无法区分aMCI组和NC组。
